Illumina (ILMN) – Research Analysts’ Recent Ratings Changes

Posted by on Oct 20th, 2023

Illumina (NASDAQ: ILMN) has recently received a number of price target changes and ratings updates:

  • 10/16/2023 – Illumina had its price target lowered by analysts at Piper Sandler from $275.00 to $200.00. They now have an “overweight” rating on the stock.
  • 10/12/2023 – Illumina had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $200.00 price target on the stock.
  • 10/5/2023 – Illumina is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 9/29/2023 – Illumina had its price target lowered by analysts at Barclays PLC from $150.00 to $100.00. They now have an “underweight” rating on the stock.
  • 9/29/2023 – Illumina had its price target lowered by analysts at Stifel Nicolaus from $225.00 to $200.00. They now have a “buy” rating on the stock.
  • 9/29/2023 – Illumina had its price target lowered by analysts at HSBC Holdings plc from $230.00 to $171.00.
  • 9/28/2023 – Illumina is now covered by analysts at Sanford C. Bernstein. They set an “underperform” rating and a $111.00 price target on the stock.
  • 9/1/2023 – Illumina had its “outperform” rating reaffirmed by analysts at Evercore ISI. They now have a $240.00 price target on the stock.

Illumina Trading Down 3.6 %

ILMN stock opened at $119.98 on Friday. Illumina, Inc. has a one year low of $119.63 and a one year high of $248.87. The stock has a market cap of $18.99 billion, a price-to-earnings ratio of -4.51, a price-to-earnings-growth ratio of 7.16 and a beta of 1.16. The company has a fifty day moving average price of $148.96 and a two-hundred day moving average price of $183.39. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.40 and a quick ratio of 1.13.

Illumina (NASDAQ:ILMN – Get Free Report) last issued its quarterly earnings data on Wednesday, August 9th. The life sciences company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.30. The firm had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $1.16 billion. Illumina had a negative net margin of 93.86% and a positive return on equity of 1.97%. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period last year, the business posted $0.57 earnings per share. Equities analysts anticipate that Illumina, Inc. will post 0.83 EPS for the current year.

Insiders Place Their Bets

In other Illumina news, SVP Susan H. Tousi sold 500 shares of Illumina stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $167.04, for a total value of $83,520.00. Following the completion of the transaction, the senior vice president now directly owns 45,524 shares of the company’s stock, valued at approximately $7,604,328.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.13% of the company’s stock.

Institutional Investors Weigh In On Illumina

Large investors have recently modified their holdings of the business. Brown Brothers Harriman & Co. increased its position in Illumina by 460.9% during the 1st quarter. Brown Brothers Harriman & Co. now owns 129 shares of the life sciences company’s stock worth $45,000 after purchasing an additional 106 shares in the last quarter. HighMark Wealth Management LLC acquired a new stake in shares of Illumina during the 1st quarter valued at $33,000. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Illumina in the 1st quarter worth about $33,000. Clearstead Trust LLC raised its position in Illumina by 125.7% in the first quarter. Clearstead Trust LLC now owns 158 shares of the life sciences company’s stock valued at $37,000 after purchasing an additional 88 shares during the last quarter. Finally, BOKF NA acquired a new stake in shares of Illumina during the first quarter valued at about $38,000. Institutional investors and hedge funds own 92.17% of the company’s stock.

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Featured Articles

Receive News & Ratings for Illumina Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc and related companies with MarketBeat.com's FREE daily email newsletter.